1
Conclusion: HMGB1 represents a useful biomarker for peritoneum evaluation in PD patients.
2
PTX3 may be a useful biomarker for assessment of risk stratification in HFNEF.
3
IHPoT may represent a clinically useful biomarker for patient treatment stratification.
4
These data suggests that MDM2 amplification may be a useful biomarker in DDLPS.
5
NRP1 could be a useful biomarker for tumor-initiating cells in lung cancer tumors.
6
Conclusion: Urine cotinine concentration is a useful biomarker for discriminating non-smokers from current smokers.
7
Furthermore, NLR might be a useful biomarker for evaluating the prognosis in cirrhotic patients.
8
Thus, serum Activin-A can be a useful biomarker to predict clinical activity during this period.
9
Moreover, glutamate uptake activity might be an useful biomarker to characterize patients with benign prognosis.
10
High frequency oscillations have been proposed as a clinically useful biomarker of seizure generating sites.
11
INPP5D mRNA expression in leukocytes may be a useful biomarker for the early stage of AD.
12
Conclusions: MiR-21 might be a potentially useful biomarker for predicting cancer prognosis in future clinical applications.
13
MGMT promoter methylation seems to be a useful biomarker for outcomes by treatment and could aid decision-making.
14
Increased blood eosinophils have proved to be a useful biomarker now used to target ICS more effectively.
15
Conclusion: These data suggest that pyroglutamate may be a new and useful biomarker for the diagnosis of NASH.
16
Conclusions: The KALRN mutation is a useful biomarker for predicting the response to immunotherapy in patients with cancer.
